Renaissance Technologies
GRCE

Renaissance Technologies’s Grace Therapeutics GRCE Stock Holding History

Renaissance Technologies’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13M Buy
243,910
+114,129
+88% +$448K ﹤0.01% 2206
2025
Q4 		$449K Buy
129,781
+45,220
+53% +$144K ﹤0.01% 2618
2025
Q3 		$252K Buy
84,561
+56,936
+206% +$178K ﹤0.01% 3072
2025
Q2 		$82K Sell
27,625
-14,556
-35% -$38.7K ﹤0.01% 3331
2025
Q1 		$96.2K Sell
42,181
-794
-2% -$2.5K ﹤0.01% 3202
2024
Q4 		$161K Buy
42,975
+26,828
+166% +$91.9K ﹤0.01% 3218
2024
Q3 		$48.4K Buy
+16,147
New +$43.2K ﹤0.01% 3349
2023
Q3 		– Sell
-11,267
Closed -$35K – 4195
2023
Q2 		$35K Sell
11,267
-3,861
-26% -$11.5K ﹤0.01% 3678
2023
Q1 		$42K Buy
+15,128
New +$54.1K ﹤0.01% 3699
2022
Q1 		– Sell
-11,630
Closed -$88K – 4546
2021
Q4 		$88K Buy
11,630
+4,395
+61% +$39.7K ﹤0.01% 3706
2021
Q3 		$87K Sell
7,235
-29,103
-80% -$573K ﹤0.01% 3336
2021
Q2 		$979K Buy
+36,338
New +$886K ﹤0.01% 2679
2021
Q1 		– Sell
-40,083
Closed -$625K – 3786
2020
Q4 		$625K Buy
+40,083
New +$463K ﹤0.01% 2724
2020
Q3 		– Sell
-20,054
Closed -$452K – 3761
2020
Q2 		$452K Buy
20,054
+17,361
+645% +$506K ﹤0.01% 2912
2020
Q1 		$49K Sell
2,693
-7,113
-73% -$252K ﹤0.01% 3324
2019
Q4 		$1.15M Buy
9,806
+4,575
+87% +$452K ﹤0.01% 2561
2019
Q3 		$475K Buy
+5,231
New +$484K ﹤0.01% 2885
2019
Q2 		– Sell
-510
Closed -$25K – 3791
2019
Q1 		$25K Buy
+510
New +$25.2K ﹤0.01% 3390
2018
Q4 		– Sell
-1,275
Closed -$79K – 3667
2018
Q3 		$79K Buy
1,275
+887
+229% +$24.6K ﹤0.01% 3255
2018
Q2 		$11K Buy
+388
New +$14.9K ﹤0.01% 3223
2018
Q1 		– Sell
-6,031
Closed -$273K – 3623
2017
Q4 		$273K Buy
6,031
+5,585
+1,252% +$375K ﹤0.01% 3045
2017
Q3 		$30K Sell
446
-119
-21% -$7.48K ﹤0.01% 3147
2017
Q2 		$36K Sell
565
-302
-35% -$18.8K ﹤0.01% 3139
2017
Q1 		$57K Sell
867
-71
-8% -$4.36K ﹤0.01% 3131
2016
Q4 		$56K Buy
938
+200
+27% +$13.4K ﹤0.01% 3159
2016
Q3 		$63K Buy
738
+94
+15% +$6.96K ﹤0.01% 3230
2016
Q2 		$43K Buy
644
+11
+2% +$747 ﹤0.01% 3245
2016
Q1 		$46K Buy
633
+198
+46% +$15.5K ﹤0.01% 3287
2015
Q4 		$53K Buy
435
+301
+225% +$35.5K ﹤0.01% 3170
2015
Q3 		$17K Buy
134
+66
+97% +$11.1K ﹤0.01% 3113
2015
Q2 		$10K Buy
+68
New +$12.6K ﹤0.01% 3194

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return

Renaissance Technologies's GRCE Position: Q1 2026 in Review

Renaissance Technologies increased its Grace Therapeutics (GRCE) stake by 88% in Q1 2026, buying an estimated $448K and bringing the position to 243,910 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2206.

Renaissance Technologies first reported a position in GRCE in Q2 2015 and has held it in 31 quarters since. The position peaked at $1.15M in Q4 2019. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

  • Renaissance Technologies held 243,910 shares of Grace Therapeutics worth $1.13M as of Q1 2026.
  • Renaissance Technologies bought 114,129 Grace Therapeutics shares in Q1 2026, an estimated $448K.
  • Grace Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2206 holding.
  • Renaissance Technologies first reported a position in Grace Therapeutics in Q2 2015 and has held it in 31 quarters since.
  • Renaissance Technologies's Grace Therapeutics position peaked at $1.15M in Q4 2019.
  • 34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.